Abstract
Increasingly a major tool for the treatment of severe psoriasis has been the selective use of biologic agents that are antibodies, known as monoclonal antibodies. These are given by injection and block the action of a specific target such as an immunological reaction involved in the development of psoriasis. One potential target for these medicines is, for instance, an immunological product known as interleukin‐17 (IL‐17).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
